Biogen Idec Expands its Portfolio with ALS Drug Candidate
By Heather Cartwright
Pharma Deals Review: Vol 2010 Issue 7 (Table of Contents)
Published: 28 Sep-2010
DOI: 10.3833/pdr.v2010.i7.1379 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Biogen Idec has signed an exclusive licensing deal with Knopp Neurosciences, potentially worth US$345 M, for a Phase II drug candidate for the treatment of amyotrophic lateral sclerosis...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS